Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.
Aaron Y LeeThomas ButtEmily ChewElvira AgronTraci E ClemonsCatherine A EganCecilia Sungmin LeeAdnan Tufailnull nullPublished in: The British journal of ophthalmology (2017)
The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy.
Keyphrases
- public health
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- healthcare
- magnetic resonance
- prognostic factors
- randomized controlled trial
- computed tomography
- type diabetes
- mental health
- metabolic syndrome
- skeletal muscle
- adipose tissue
- deep learning
- global health
- open label